Baclofen for alcohol withdrawal

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 8, 2017, Pages

  Liu, Jia ^a   Wang, Lu Ning ^b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; ALCOHOL; BACLOFEN; CHLORDIAZEPOXIDE; DIAZEPAM;

ALCOHOL-INDUCED DISORDERS; HUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); SUBSTANCE WITHDRAWAL SYNDROME;

ALCOHOL-INDUCED DISORDERS; BACLOFEN; CHLORDIAZEPOXIDE; DIAZEPAM; ETHANOL; GABA AGONISTS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 85027698397     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD008502.pub5     Document Type: Review

References (60)

1. Addolorato G, Leggio L, Abenavoli L, Agabio R, Caputo F, Capristo E, et al. Baclofen in the treatment of alcohol withdrawal syndrome: a comparative study vs diazepam. American Journal of Medicine 2006;119(3):276.e13-8. 3318660
2. Girish K, Vikram Reddy K, Pandit LV, Pundarikaksha HP, Vijendra R, Vasundara K, et al. A randomized, open-label, standard controlled, parallel group study of efficacy and safety of baclofen, and chlordiazepoxide in uncomplicated alcohol withdrawal syndrome. Biomedical Journal 2016;39(1):72-80. 6614404
3. Lyon JE, Khan RA, Gessert CE, Larson PM, Renier CM. Treating alcohol withdrawal with oral baclofen: a randomized, double-blind, placebo-controlled trial. Journal of Hospital Medicine 2011;6(8):469-74. 3318662
4. Addolorato G, Caputo F, Capristo E, Domenicali M, Bernardi M, Janiri L, et al. Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomised controlled study. Alcohol and Alcoholism (Oxford, Oxfordshire) 2002;37(5):504-8. 3318664
5. Addolorato G, Leggio L, Ferrulli A, Cardone S, Vonghia L, Mirijello A, et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet 2007;370(9603):1915-22. 3318666
6. Addolorato G, Leggio L, Ferrulli A, Cardone S, Bedogni G, Caputo F, et al. Dose-response effect of baclofen in reducing daily alcohol intake in alcohol dependence: secondary analysis of a randomized, double-blind, placebo-controlled trial. Alcohol and Alcoholism (Oxford, Oxfordshire) 2011;46(3):312-7. 3318668
7. Beraha EM, Salemink E, Goudriaan AE, Bakker A, de Jong D, Smits N, et al. Efficacy and safety of high-dose baclofen for the treatment of alcohol dependence: a multicentre, randomised, double-blind controlled trial. European Neuropsychopharmacology 2016;26(12):1950-9. 6614406
8. Farokhnia M, Edwards SM, Bollinger J, Amodio J, Zywiak WH, Tidey JW, et al. Baclofen as a pharmacotherapy for the treatment of concurrent alcohol and nicotine dependence: a double-blind, placebo-controlled, randomized trial. Neuropsychopharmacology 2015;40(6):1560. 6614408
9. Franchitto N, Pelissier F, Lauque D, Simon N, Lançon C. Self-intoxication with baclofen in alcohol-dependent patients with co-existing psychiatric illness: an emergency department case series. Alcohol and Alcoholism (Oxford, Oxfordshire) 2014;49(1):79-83. 3318670
10. Garbutt JC, Flannery B. Baclofen for alcoholism. Lancet 2007;370:1884-5. 3318672
11. Garbutt JC, Kampov-Polevoy AB, Gallop R, Kalka-Juhl L, Flannery BA. Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial. Alcoholism, Clinical and Experimental Research 2010;34:1849-57. 3318674
12. Geisel O, Hellweg R, Müller CA. Serum levels of brain-derived neurotrophic factor in alcohol-dependent patients receiving high-dose baclofen. Psychiatry Research 2016;240:177-80. 6614410
13. Gupta M, Verma P, Rastogi R, Arora S, Elwadhi D. Randomized open-label trial of baclofen for relapse prevention in alcohol dependence. American Journal of Drug and Alcohol Abuse 2017;43:324-31. 6614412
14. Hauser P, Fuller B, Ho SB, Thuras P, Kern S, Dieperink E. The safety and efficacy of baclofen to reduce alcohol use in veterans with chronic hepatitis C: a randomized clinical trial. Addiction 2017;112:1173-83. 6614414
15. Imbert B, Alvarez J, Simon N. Anticraving effect of baclofen in alcohol-dependent patients. Alcoholism, Clinical and Experimental Research 2015;39:1602-8. 6614416
16. Krupitsky EM, Burakov AM, Ivanov VB, Krandashova GF, Lapin IP, Grinenko AJ, et al. Baclofen administration for the treatment of affective disorders in alcoholic patients. Drug and Alcohol Dependence 1993;33:157-63. 3318678
17. Krupitsky EM, Burakov AM, Grinenko AIa, Borodkin IuS. Effect of pharmacotherapy of affective disorders on the psycho-semantics of alcoholic patients. Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova / Ministerstvo Zdravookhraneniia i Meditsinskoi Promyshlennosti Rossiiskoi Federatsii, Vserossiiskoe Obshchestvo Nevrologov [i] Vserossiiskoe Obshchestvo Psikhiatrov 1995;95:67-71. 3318676
18. Krupitsky EM, Rybakova KV, Kiselev AS, Alexeeva YV, Berntsev VA, Chekhlaty EI, et al. Double blind placebo controlled randomized pilot clinical trial of baclofen (Baclosan®) for alcohol dependence. Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova / Ministerstvo Zdravookhraneniia i Meditsinskoi Promyshlennosti Rossiiskoi Federatsii, Vserossiiskoe Obshchestvo Nevrologov [i] Vserossiiskoe Obshchestvo Psikhiatrov 2015;115:53-62. 6614418
19. Leggio L, Ferrulli A, Zambon A, Caputo F, Kenna GA, Swift RM, et al. Baclofen promotes alcohol abstinence in alcohol dependent cirrhotic patients with hepatitis C virus (HCV) infection. Addictive Behaviors 2012;37:561-4. 3318680
20. Leggio L, Zywiak WH, McGeary JE, Edwards S, Fricchione SR, Shoaff JR, et al. A human laboratory pilot study with baclofen in alcoholic individuals. Pharmacology, Biochemistry, and Behavior 2013;103:784-91. 3318682
21. Morley KC, Leung S, Baillie A, Haber PS. The efficacy and biobehavioural basis of baclofen in the treatment of alcoholic liver disease (BacALD): study protocol for a randomised controlled trial. Contemporary Clinical Trials 2013;36:348-55. 3318684
22. Müller CA, Geisel O, Pelz P, Higl V, Krüger J, Stickel A, et al. High-dose baclofen for the treatment of alcohol dependence (BACLAD study): a randomized, placebo-controlled trial. European Neuropsychopharmacology 2015;25:1167-77. 6614420
23. Pommier P, Debaty G, Bartoli M, Viglino D, Carpentier F, Danel V, et al. Severity of deliberate acute baclofen poisoning: a nonconcurrent cohort study. Basic & Clinical Pharmacology & Toxicology 2014;114:360-4. 3318686
24. Ponizovsky AM, Rosca P, Aronovich E, Weizman A, Grinshpoon A. Baclofen as add-on to standard psychosocial treatment for alcohol dependence: a randomized, double-blind, placebo-controlled trial with 1 year follow-up. Journal of Substance Abuse Treatment 2015;52:24-30. 6614422
25. Rigal L, Legay Hoang L, Alexandre-Dubroeucq C, Pinot J, Le Jeunne C, Jaury P. Tolerability of high-dose baclofen in the treatment of patients with alcohol disorders: a retrospective study. Alcohol and Alcoholism (Oxford, Oxfordshire) 2015;50:551-7. 6614424
26. Rolland B, Auffret M, Labreuche J, Lapeyre-Mestre M, Dib M, Kemkem A, et al. Phone-based safety monitoring of the first year of baclofen treatment for alcohol use disorder: the BACLOPHONE cohort study protocol. Expert Opinion on Drug Safety 2017;16:125-32. 6614426
27. Simioni N, Preda C, Deken V, Bence C, Cottencin O, Rolland B. Characteristics of patients with alcohol dependence seeking baclofen treatment in France: a two-centre comparative cohort study. Alcohol and Alcoholism (Oxford, Oxfordshire) 2016;51:664-9. 6614428
28. Vourc'h M, Feuillet F, Mahe PJ, Sebille V, Asehnoune K, BACLOREA trial group. Baclofen to prevent agitation in alcohol-addicted patients in the ICU: study protocol for a randomised controlled trial. Trials 2016;17:415. 6614430
29. NCT02052440. Preventing alcohol withdrawal syndrome with oral baclofen. clinicaltrials.gov/show/NCT02052440 (first received 30 January 2014). 6614432
30. Addolorato G, Caputo F, Capristo E, Janiri L, Bernardi M, Agabio R, et al. Rapid suppression of alcohol withdrawal syndrome by baclofen. American Journal of Medicine 2002;112:226-9.
31. Addolorato G, Leggio L, Abenavoli L, DeLorenzi G, Parente A, Caputo F, et al. Suppression of alcohol delirium tremens by baclofen administration: a case report. Clinical Neuropharmacology 2003;26:258-62.
32. Amato L, Minozzi S, Vecchi S, Davoli M. Benzodiazepines for alcohol withdrawal. Cochrane Database of Systematic Reviews 2010, Issue 3. [DOI: 10.1002/14651858.CD005063.pub3]
33. Amato L, Minozzi S, Davoli M. Efficacy and safety of pharmacological interventions for the treatment of the alcohol withdrawal syndrome. Cochrane Database of Systematic Reviews 2011, Issue 6. [DOI: 10.1002/14651858.CD008537.pub2]
34. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. Washington (DC): American Psychiatric Association, 1994.
35. Bowery NG, Hudson AL, Price GW. GABAA and GABAB receptor site distribution in the rat central nervous system. Neuroscience 1987;20:365-83.
36. Carter LP, Koek W, France CP. Behavioral analyses of GHB: receptor mechanisms. Pharmacology & Therapeutics 2009;121:100-14.
37. Colombo G, Agabio R, Carai MA, Lobina C, Pani M, Reali R, et al. Ability of baclofen in reducing alcohol intake and withdrawal severity: I - preclinical evidence. Alcoholism, Clinical and Experimental Research 2000;24:58-66.
38. Davidoff RA. Antispasticity drugs: mechanisms of action. Annals of Neurology 1985;17:107-16.
39. Dissanaike S, Halldorsson A, Frezza EE, Griswold J. An ethanol protocol to prevent alcohol withdrawal syndrome. Journal of the American College of Surgeons 2006;203:186-91.
40. Dodd PR, Beckmann AM, Davidson MS, Wilce PA. Glutamate-mediated transmission, alcohol, and alcoholism. Neurochemistry International 2000;37:509-33.
41. Fiellin DA, O'Connor PG, Holmboe ES, Horwitz RI. Risk for delirium tremens in patients with alcohol withdrawal syndrome. Substance Abuse 2002;23:83-94.
42. Schünemann H, Brozek J, Guyatt G, Oxman A, editor(s). Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. Updated October 2013. gdt.guidelinedevelopment.org/app/handbook/handbook.html (accessed prior to 8 August 2017).
43. Higgins JPT, Altman DG, Sterne JAC. Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
44. Knapp DJ, Overstreet DH, Breese GR. Baclofen blocks expression and sensitization of anxiety-like behavior in an animal model of repeated stress and ethanol withdrawal. Alcoholism, Clinical and Experimental Research 2007;31:582-95.
45. Leggio L, Kenna GA, Swift RM. New developments for the pharmacological treatment of alcohol withdrawal syndrome. A focus on non-benzodiazepine GABAergic medications. Biological Psychiatry 2008;32:1106-17.
46. Lejoyeux M, Solomon J, Adès J. Benzodiazepine treatment for alcohol-dependent patients. Alcohol and Alcoholism (Oxford, Oxfordshire) 1998;33:563-75.
47. Lerner WD, Fallon HJ. The alcohol withdrawal syndrome. New England Journal of Medicine 1985;313:951-2.
48. Liang J, Cagetti E, Olsen RW, Spigelman I. Altered pharmacology of synaptic and extrasynaptic GABAA receptors on CA1 hippocampal neurons is consistent with subunit changes in a model of alcohol withdrawal and dependence. Journal of Pharmacology and Experimental Therapeutics 2004;310:1234-45.
49. Mayo-Smith MF. Pharmacological management of alcohol withdrawal. A meta analysis and evidence-based practice guideline. American Society of Addiction Medicine Working Group on Pharmacological Management of Alcohol Withdrawal. JAMA 1997;278:144-51.
50. McDonald LM, Sheppard WF, Staveley SM, Sohal B, Tattersall FD, Hutson PH. Discriminative stimulus effects of tiagabine and related GABAergic drugs in rats. Psychopharmacology 2008;197:591-600.
51. Minozzi S, Amato L, Vecchi S, Davoli M. Anticonvulsants for alcohol withdrawal. Cochrane Database of Systematic Reviews 2010, Issue 3. [DOI: 10.1002/14651858.CD005064.pub3]
52. Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
53. Room R, Babor T, Rehm J. Alcohol and public health. Lancet 2005;365:519-30.
54. Stallings W, Schrader S. Baclofen as prophylaxis and treatment for alcohol withdrawal: a retrospective chart review. Journal of Oklahoma State Medical Association 2007;100:354-60.
55. Weiss F, Porrino LJ. Behavioral neurobiology of alcohol addiction: recent advances and challenges. Journal of Neuroscience 2002;22:3332-7.
56. Westerink BHC, Kwint H-F, deVries JB. The pharmacology of mesolimbic dopamine neurons: a dual-probe micro dialysis study in the ventral tegmental area and nucleus accumbens of the rat brain. Journal of Neuroscience 1996;16:2605-11.
57. Liu J, Wang L. Baclofen for alcohol withdrawal. Cochrane Database of Systematic Reviews 2010, Issue 5. [DOI: 10.1002/14651858.CD008502]
58. Liu J, Wang L. Baclofen for alcohol withdrawal. Cochrane Database of Systematic Reviews 2011, Issue 1. [DOI: 10.1002/14651858.CD008502.pub2]
59. Liu J, Wang LN. Baclofen for alcohol withdrawal. Cochrane Database of Systematic Reviews 2013, Issue 2. [DOI: 10.1002/14651858.CD008502.pub3]
60. Liu J, Wang LN. Baclofen for alcohol withdrawal. Cochrane Database of Systematic Reviews 2015, Issue 4. [DOI: 10.1002/14651858.CD008502.pub4]